Skip to content

Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)

A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01763567
Acronym
MAHI
Enrollment
19
Registered
2013-01-09
Start date
2012-03-31
Completion date
2012-09-30
Last updated
2015-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia

Keywords

Medtronic, Diabetes, Hospital, Continuous Glucose Monitor, Intensive Care Unit

Brief summary

The purpose of this study is to assess safety and device performance of the Medtronic Hospital Glucose Management System (HGMS) for up to 72-hours.

Detailed description

Assess safety and device performance of the Medtronic HGMS in the critically-ill setting and analyze the following: 1. Device Performance: * Functionality of HGMS * Alerts/Alarms Specificity and Sensitivity * System Workflow 2. Safety: * Descriptive statistics will be used to characterize safety events * Moderate and severe anticipated device and procedure related adverse events * All serious adverse events and unanticipated adverse device effects related events

Interventions

None listed

Sponsors

Medtronic Diabetes
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is at least 18 years old 2. Subject is admitted to the ICU 3. Subject has a treatment regimen that includes a glucose target range of ≥140 mg/dl 4. Subject has a treatment regimen that includes an intended continuous intravenous insulin for at least 24 hours a. Including patients with no previous diagnosis of Diabetes Mellitus 5. Subject has anticipated life expectancy greater than 96 hours 6. Subject has recent platelet count greater than 30,000 per micro-liter

Exclusion criteria

1. Subject currently has a suspected or diagnosed medical condition that, in the opinion of the Investigator, warrants exclusion from the study or prevents the subject from completing the study 2. Subject is currently participating in another investigational drug or device study 3. Subject is pregnant, as determined by hospital admission 4. Subject is receiving treatment that includes Hydroxyurea.

Design outcomes

Primary

MeasureTime frameDescription
Device Performance: Accuracy of HGMSup to 72 hoursMean Absolute Relative Difference (MARD), calculated as the absolute difference of \[(sensor glucose values - iSTAT glucose values) / iSTAT glucose values\]. The portable i-STAT handheld makes patient-side testing easy: * Requires no special sample preparation or user calibration; maintenance is minimal * Weighs 18 ounces, making it portable * Patient-side testing is as easy as entering the operator and patient information into the handheld, inserting one of the several filled test cartridges, and then viewing test results: * The system prompts users step by step through the testing process * Operator and patient information can be entered via barcode scanner * Operator lockout prevents unauthorized users from performing or viewing test results * Test results are uploaded automatically when the i-STAT handheld is placed in a downloader

Other

MeasureTime frameDescription
Functionality of HGMS: Alerts and Alarms - % of Hypo Events Correctly Detectedup to 72 hoursThe device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes below 70 mg/dL setting levels. The % of hypo events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.
Functionality of HGMS: Alerts and Alarms - % of Hyper Events Correctly Detected72 hoursThe device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes above 250 mg/dL setting levels. The % of hyper events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.
Functionality of HGMS: Alerts and Alarms - % of Hypo False AlertUp to 72 hoursDefinition of % of hypo false alert: within 30 minutes before or after the sensor alarmed at 70 mg/dL, there is no reference blood glucose value (i-STAT) that goes below 70 mg/dL. The % of hypo false alert was calculated as: total number of false events divided by total number of events from all 19 participants. NOTE: % of Hypo False Alert and % Hypo Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.
Functionality of HGMS: Alerts and Alarms - % of Hyper False AlertUp to 72 hoursDefinition of % of Hyper False Alert: within 30 minutes before or after the sensor alarmed at 250 mg/dL, there is no reference blood glucose value (i-STAT) that goes above 250mg/dL . The % of hyper false alert was calculated as: total number of false events divided by total number of events from all 19 participants. NOTE: % of Hyper False Alert and % Hyper Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.

Countries

United States

Participant flow

Participants by arm

ArmCount
Oberservation Arm
To assess safety and device performance for the Hospital Glucose Managment system
19
Total19

Baseline characteristics

CharacteristicOberservation Arm
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
10 Participants
Age, Categorical
Between 18 and 65 years
9 Participants
Age, Continuous64.2 years
STANDARD_DEVIATION 12.1
Region of Enrollment
United States
19 participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 19
serious
Total, serious adverse events
0 / 19

Outcome results

Primary

Device Performance: Accuracy of HGMS

Mean Absolute Relative Difference (MARD), calculated as the absolute difference of \[(sensor glucose values - iSTAT glucose values) / iSTAT glucose values\]. The portable i-STAT handheld makes patient-side testing easy: * Requires no special sample preparation or user calibration; maintenance is minimal * Weighs 18 ounces, making it portable * Patient-side testing is as easy as entering the operator and patient information into the handheld, inserting one of the several filled test cartridges, and then viewing test results: * The system prompts users step by step through the testing process * Operator and patient information can be entered via barcode scanner * Operator lockout prevents unauthorized users from performing or viewing test results * Test results are uploaded automatically when the i-STAT handheld is placed in a downloader

Time frame: up to 72 hours

Population: To assess safety and device performance for the Hospital Glucose Managment system

ArmMeasureValue (MEAN)Dispersion
Oberservation ArmDevice Performance: Accuracy of HGMS12.8 percent differenceStandard Deviation 9.5
Other Pre-specified

Functionality of HGMS: Alerts and Alarms - % of Hyper Events Correctly Detected

The device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes above 250 mg/dL setting levels. The % of hyper events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.

Time frame: 72 hours

ArmMeasureValue (NUMBER)
Oberservation ArmFunctionality of HGMS: Alerts and Alarms - % of Hyper Events Correctly Detected88.9 percentage of total events
Other Pre-specified

Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert

Definition of % of Hyper False Alert: within 30 minutes before or after the sensor alarmed at 250 mg/dL, there is no reference blood glucose value (i-STAT) that goes above 250mg/dL . The % of hyper false alert was calculated as: total number of false events divided by total number of events from all 19 participants. NOTE: % of Hyper False Alert and % Hyper Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.

Time frame: Up to 72 hours

ArmMeasureValue (NUMBER)
Oberservation ArmFunctionality of HGMS: Alerts and Alarms - % of Hyper False Alert56.5 percentage of all alerts
Other Pre-specified

Functionality of HGMS: Alerts and Alarms - % of Hypo Events Correctly Detected

The device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes below 70 mg/dL setting levels. The % of hypo events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.

Time frame: up to 72 hours

ArmMeasureValue (NUMBER)
Oberservation ArmFunctionality of HGMS: Alerts and Alarms - % of Hypo Events Correctly Detected16.7 percentage of total events
Other Pre-specified

Functionality of HGMS: Alerts and Alarms - % of Hypo False Alert

Definition of % of hypo false alert: within 30 minutes before or after the sensor alarmed at 70 mg/dL, there is no reference blood glucose value (i-STAT) that goes below 70 mg/dL. The % of hypo false alert was calculated as: total number of false events divided by total number of events from all 19 participants. NOTE: % of Hypo False Alert and % Hypo Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.

Time frame: Up to 72 hours

ArmMeasureValue (NUMBER)
Oberservation ArmFunctionality of HGMS: Alerts and Alarms - % of Hypo False Alert85.8 percentage of all alerts

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026